Atrys Health (XMAD:ATRY) Financial Strength: 2 (As of Dec. 2025) — 50% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:ATRY Atrys Health SA XMAD:ATRY
62 GF Score
Price €2.65
GF Value €3.19
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Atrys Health Financial Strength?

Atrys Health XMAD:ATRY -0.56% 62 Financial Strength is 2 as of Dec. 2025, which is 50% below its 10-year median of 4.00. GuruFocus rates XMAD:ATRY with a GF Score™ of 62/100 and a GF Value™ of €3.19 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Atrys Health has the Financial Strength Rank of 2. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.

Warning Sign:

Atrys Health SA displays poor financial strength. Usually, this is caused by too much debt for the company.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.

A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Atrys Health did not have earnings to cover the interest expense. Atrys Health's debt to revenue ratio for the quarter that ended in Dec. 2025 was 1.84. As of today, Atrys Health's Altman Z-Score is -0.05.


Atrys Health  (XMAD:ATRY) Financial Strength Explanation

The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Atrys Health has the Financial Strength Rank of 2. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.


Atrys Health Financial Strength Related Terms


XMAD:ATRY vs VRTX, REGN, RVMD: Financial Strength Comparison

For the Biotechnology subindustry, Atrys Health's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atrys Health Financial Strength vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atrys Health's Financial Strength distribution charts can be found below:

* The bar in red indicates where Atrys Health's Financial Strength falls into.


XMAD:ATRY
62GF Score
Atrys Health SA XMAD:ATRY
Financial Strength is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrys Health Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Atrys Health's Interest Expense for the months ended in Dec. 2025 was €-8.9 Mil. Its Operating Income for the months ended in Dec. 2025 was €-5.9 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was €34.0 Mil.

Atrys Health's Interest Coverage for the quarter that ended in Dec. 2025 is

Atrys Health did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Atrys Health's Debt to Revenue Ratio for the quarter that ended in Dec. 2025 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2025 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(223.902 + 33.964) / 139.89
=1.84

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Atrys Health has a Z-score of -0.05, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -0.05 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Financial Strength →
What does a Financial Strength of 2 mean?
Atrys Health (XMAD:ATRY) has a Financial Strength of 2 as of Dec. 2025. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Atrys Health and its competitors. This is 50% below median its historical median of 4.00. Over the past decade, Atrys Health's Financial Strength has ranged from 2.00 to 7.00.
Is Atrys Health's Financial Strength too high?
Atrys Health's current Financial Strength of 2 is 50% below median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 7.00. Overall, Atrys Health has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Atrys Health's Financial Strength compare to VRTX and REGN?
Atrys Health's Financial Strength of 2 can be compared against companies in the Biotechnology industry. Historically, Atrys Health's own Financial Strength has ranged from 2.00 to 7.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Financial Strength for a Biotechnology company?
A good Financial Strength depends on the Biotechnology industry context. However, Financial Strength should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Financial Strength mean?
A high Financial Strength can signal that a stock is expensive relative to its fundamentals. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Atrys Health and its competitors. Atrys Health's current Financial Strength is 2, which is 50% below median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrys Health stock overvalued right now?
Based on GuruFocus' analysis, Atrys Health (XMAD:ATRY) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.19, compared to a current price of €2.65 — trading 17.1% below its estimated fair value. The current Financial Strength is 2, which is 50% below median its 10-year median of 4.00. Atrys Health's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Financial Strength calculated?
Financial Strength is calculated from a company's financial statements. For Atrys Health (XMAD:ATRY), the current Financial Strength is 2 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Atrys Health (XMAD:ATRY) Overvalued in 2026?

Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued. The current stock price of €2.65 is trading 17.1% below its estimated GF Value™ of €3.19. GuruFocus considers Atrys Health to be Modestly Undervalued.

Key valuation signals for XMAD:ATRY:

  • Financial Strength: 2 (50% below median its 10-year median of 4.00)
  • GF Value™: €3.19 vs. price of €2.65 (17.1% below fair value)
  • GF Score™: 62/100 with 5 warning signs

No single metric tells the full story. See the XMAD:ATRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Atrys Health Business Description

Other Exchanges A2T:Germany
Address Calle Provenca, 392 planta baja, Barcelona, ESP, 08025
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
62GF Score

Get the complete analysis for XMAD:ATRY

Financial Strength is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.65
Price
€3.19
GF Value